Ishizuka Y, Kamisaki T, Okamoto N, Matsuda M, Shimazaki I, Kimura I, Kamiya A, Kataoka M, Kawashima M, Terashima K
Research Laboratories, Roussel Morishita Co., Ltd., Shiga, Japan.
Arzneimittelforschung. 1994 May;44(5):620-6.
1,6-dihydro-2-[2-(2-methylpropoxy)anilino]-6-oxo-5-pyrimidinecarbo xylic acid, (MAR-99, CAS 98772-05-5) (10-30 mg/kg i.g.) improved the reduction of gastric blood flow rate induced by the administration of 99.5% ethanol or acidified-acetylsalicylic acid (ASA). In addition, MAR-99 (3 x 10(-6)-3 x 10(-5) mol/l) protected dose-dependently the damage of epithelial cells induced by ulcerogenic agents such as ethanol or acidified-ASA. MAR-99 (1-10 mg/kg p.o.) prevented dose-dependently the reduction of hexosamine content in glandular stomach. Furthermore, MAR-99 (10-30 mg/kg i.g.) improved the decrease in gastric potential difference induced by 99.5% ethanol and acidified-ASA. MAR-99 (10-30 mg/kg p.o.) significantly inhibited the lesion formation induced by 99.5% ethanol and such effect of this compound was not attenuated by the pretreatment with indomethacin. Furthermore MAR-99 (10 and 30 mg/kg p.o.) had no effect on the prostaglandins (PGE2 and I2) contents in the stomach of normal rats. In pylorus-ligated rats, MAR-99 (3-100 mg/kg i.d.) showed a weak or no effect on acidity and pepsin activity in gastric juice, although this compound decreased dose-dependently the volume of gastric juice. In perfused stomachs, MAR-99 (30-100 mg/kg i.d.) slightly prevented the acid secretion induced by carbachol and pentagastrin. However, MAR-99 did not affect the acid secretion stimulated by histamine. These results indicated that anti-ulcer effect of MAR-99 was mainly due to maintenance of the gastric mucosal resistance.
1,6 - 二氢 - 2 - [2 - (2 - 甲基丙氧基)苯胺基] - 6 - 氧代 - 5 - 嘧啶羧酸(MAR - 99,化学物质登记号98772 - 05 - 5)(腹腔注射10 - 30毫克/千克)可改善因给予99.5%乙醇或酸化乙酰水杨酸(ASA)所致的胃血流量降低情况。此外,MAR - 99(3×10⁻⁶ - 3×10⁻⁵摩尔/升)可剂量依赖性地保护由乙醇或酸化ASA等致溃疡剂引起的上皮细胞损伤。MAR - 99(口服1 - 10毫克/千克)可剂量依赖性地预防腺胃中氨基己糖含量的降低。此外,MAR - 99(腹腔注射10 - 30毫克/千克)可改善由99.5%乙醇和酸化ASA引起的胃电位差降低。MAR - 99(口服10 - 30毫克/千克)可显著抑制由99.5%乙醇诱导的损伤形成,且吲哚美辛预处理不会减弱该化合物的这种作用。此外,MAR - 99(口服10和30毫克/千克)对正常大鼠胃中前列腺素(PGE₂和I₂)含量无影响。在幽门结扎大鼠中,MAR - 99(十二指肠内注射3 - 100毫克/千克)对胃液酸度和胃蛋白酶活性显示出微弱作用或无作用,尽管该化合物可剂量依赖性地减少胃液体积。在灌注胃中,MAR - 99(十二指肠内注射30 - 100毫克/千克)可轻微预防卡巴胆碱和五肽胃泌素诱导的胃酸分泌。然而,MAR - 99不影响组胺刺激的胃酸分泌。这些结果表明,MAR - 99的抗溃疡作用主要归因于维持胃黏膜抵抗力。